Sibelium: Advanced Migraine Prophylaxis Therapy
Sibelium
| Product dosage: 10 mg | |||
|---|---|---|---|
| Package (num) | Per tab | Price | Buy |
| 30 | 1.60 $ | 47.97 $ (0%) | 🛒 Add to cart |
| 60 | 0.88 $ | 95.94 $ 52.65 $ (45%) | 🛒 Add to cart |
| 90 | 0.65 $ | 143.91 $ 58.50 $ (59%) | 🛒 Add to cart |
| 120 | 0.52 $ | 191.88 $ 62.01 $ (68%) | 🛒 Add to cart |
| 180 | 0.36 $
Best per tab | 287.82 $ 64.35 $ (78%) | 🛒 Add to cart |
| Product dosage: 5 mg | |||
|---|---|---|---|
| Package (num) | Per tab | Price | Buy |
| 30 | 1.40 $ | 42.12 $ (0%) | 🛒 Add to cart |
| 60 | 0.80 $ | 84.24 $ 47.97 $ (43%) | 🛒 Add to cart |
| 90 | 0.56 $ | 126.36 $ 50.31 $ (60%) | 🛒 Add to cart |
| 120 | 0.46 $ | 168.48 $ 54.99 $ (67%) | 🛒 Add to cart |
| 180 | 0.32 $
Best per tab | 252.72 $ 57.33 $ (77%) | 🛒 Add to cart |
Synonyms | |||
Sibelium, with the active ingredient flunarizine dihydrochloride, is a highly selective calcium channel blocker specifically indicated for the prophylactic management of migraine. It represents a cornerstone in preventive neurological therapy, designed to reduce the frequency and severity of migraine attacks, thereby significantly improving patients’ quality of life. Its mechanism of action, targeting vascular smooth muscle and neuronal calcium overload, offers a targeted approach for chronic sufferers unresponsive to acute treatments alone.
Features
- Active ingredient: Flunarizine dihydrochloride 10mg
- Pharmacological class: Selective calcium channel blocker
- Specifically targets T-type and L-type voltage-gated calcium channels
- Exhibits additional histamine H1-blocking properties
- Long half-life allowing for once-daily dosing
- Available in tablet form for oral administration
Benefits
- Significantly reduces the frequency of migraine attacks by modulating cortical spreading depression and vascular tone.
- Decreases the intensity and duration of migraine episodes when they occur, lessening the need for acute rescue medications.
- Improves overall patient functionality and reduces disability days associated with chronic migraine.
- Demonstrates a favorable long-term safety profile for sustained prophylactic use in appropriate patient populations.
- Can lead to a reduction in associated symptoms such as photophobia, phonophobia, and nausea.
- Offers a non-beta-blocking alternative for patients with contraindications to other first-line prophylactic agents.
Common use
Sibelium is primarily prescribed for the prophylaxis of classic and common migraine. It is indicated for patients experiencing frequent or severe migraine attacks that significantly impair daily activities, typically defined as four or more migraine days per month. It is also utilized in cases where other prophylactic agents have proven ineffective or intolerable. Its use extends to certain vestibular disorders, such as Ménière’s disease and vertigo of central origin, due to its effect on calcium-mediated neuronal excitability. The medication is intended for long-term management rather than acute abortive therapy.
Dosage and direction
The recommended starting dose for migraine prophylaxis in adults is 10mg once daily, taken in the evening to mitigate potential drowsiness. For patients under 18 years of age, the safety and efficacy have not been fully established. In elderly patients or those with hepatic impairment, a lower starting dose of 5mg daily may be prudent. Treatment should be initiated with a low dose and gradually increased based on therapeutic response and tolerability. The full prophylactic effect may take several weeks to manifest. Continuous treatment for at least 4-6 months is generally recommended before evaluating efficacy. The tablets should be swallowed whole with water, with or without food, though consistent administration is advised.
Precautions
Patients should be cautioned regarding the potential for drowsiness, which may impair the ability to drive or operate machinery, particularly during the initial treatment phase. Regular monitoring of body weight is recommended due to the possibility of weight gain. Extrapyramidal symptoms, though rare, may occur, especially in elderly patients or those with a history of Parkinson’s disease. Periodic evaluation of depressive symptoms is advised, as flunarizine may exacerbate pre-existing depression. Use with caution in patients with pre-existing cardiac conduction abnormalities or those taking other QT-prolonging agents. Liver function tests may be considered during prolonged therapy.
Contraindications
Sibelium is contraindicated in patients with known hypersensitivity to flunarizine or any components of the formulation. It should not be used in patients with a history of depressive illness, especially with suicidal tendencies, or pre-existing Parkinson’s disease and other extrapyramidal disorders. Contraindications extend to patients with severe hepatic impairment (Child-Pugh class C). Concomitant use with other calcium channel blockers is not recommended due to potential additive effects. It is contraindicated in pregnancy and lactation unless the potential benefit justifies the potential risk to the fetus or infant.
Possible side effects
The most commonly reported side effects include drowsiness (approximately 15-20% of patients), weight gain (up to 10%), and fatigue. Less frequently, patients may experience gastrointestinal disturbances such as nausea, heartburn, or abdominal pain. Extrapyramidal symptoms, including tremor, rigidity, and akathisia, may occur, particularly with long-term use or higher doses. Other potential adverse reactions include depression, anxiety, insomnia, and skin reactions such as rash. Rare but serious side effects include galactorrhea, gynecomastia, and QT interval prolongation on ECG. Patients should report any persistent or severe side effects to their healthcare provider.
Drug interaction
Sibelium may potentiate the sedative effects of alcohol, benzodiazepines, opioids, and other CNS depressants. Concomitant use with other calcium channel blockers (e.g., verapamil, diltiazem) may lead to additive cardiovascular effects. It may enhance the effects of antihypertensive medications, requiring blood pressure monitoring. CYP2D6 inhibitors may increase flunarizine plasma concentrations. Concurrent use with dopamine antagonists or antipsychotics may increase the risk of extrapyramidal symptoms. Caution is advised with drugs that prolong the QT interval, such as certain antidepressants, antipsychotics, and antibiotics.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next scheduled dose. In that case, the missed dose should be skipped, and the regular dosing schedule resumed. Doubling the dose to make up for a missed one is not recommended, as it may increase the risk of side effects. Patients should be advised to maintain a consistent dosing routine, ideally taking the medication at the same time each evening to maximize prophylactic efficacy and minimize forgetfulness.
Overdose
Symptoms of overdose may include severe drowsiness, agitation, hypotension, bradycardia, and extrapyramidal symptoms. In cases of suspected overdose, immediate medical attention should be sought. Gastric lavage may be considered if ingestion was recent. Activated charcoal can be administered to reduce absorption. Treatment is primarily supportive and symptomatic, including monitoring of vital signs and ECG. There is no specific antidote for flunarizine overdose. Hemodialysis is unlikely to be effective due to the drug’s high protein binding and extensive tissue distribution.
Storage
Store at room temperature (15-30°C) in a dry place, protected from light and moisture. Keep the container tightly closed to prevent degradation. Do not store in the bathroom or near sinks. Keep out of reach of children and pets. Do not use beyond the expiration date printed on the packaging. Properly discard any unused medication through a medicine take-back program or according to local guidelines, avoiding flushing down the toilet or drainage systems.
Disclaimer
This information is intended for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting, changing, or stopping any medication. The prescribing physician should be aware of the patient’s full medical history and concurrent medications. Dosage and administration may vary based on individual patient factors. The patient information leaflet provided with the medication should be read thoroughly before use.
Reviews
Clinical studies and post-marketing surveillance demonstrate that Sibelium provides effective migraine prophylaxis in approximately 60-70% of patients, with a significant reduction in attack frequency and severity. Many patients report improved quality of life and reduced reliance on acute medications. The once-daily dosing is frequently cited as convenient. However, some patients discontinue treatment due to side effects, particularly weight gain and drowsiness. Long-term users often emphasize the importance of regular follow-up with their neurologist to monitor efficacy and tolerability. Overall, it remains a valuable option in the migraine prophylactic arsenal, particularly for patients who have not responded to first-line therapies.